CXCR7 Inhibiting Polypeptides for Head and Neck Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for head and neck cancers lack effective treatments due to poor understanding of CXCR7 biology and limited availability of anti-CXCR7 drugs, with existing small molecule antagonists showing side effects and limited immunogenicity, necessitating the development of potent and specific anti-CXCR7 agents for diagnostic, preventive, and therapeutic applications.
Innovation Solution
Development of polypeptides comprising immunoglobulin single variable domains directed against CXCR7, combined with serum albumin binding domains to enhance half-life and specificity, for targeting CXCR7 in human tumors, including the use of Nanobodies that inhibit CXCR7 signaling and tumor growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule antagonists (CCX733, CCX266) are used to block CXCR7, then CXCR7-mediated signaling is inhibited, but side effects and limited immunogenicity occur
Solution Approach 1:
The patent changes the molecular class parameter from small molecules to polypeptides/antibodies, fundamentally altering the therapeutic agent's properties to achieve better safety profile while maintaining CXCR7 inhibition efficacy
Solution Approach 2:
The patent employs composite antibody structures including heavy chain-only antibodies and bispecific antibodies that combine CXCR7 binding capability with enhanced pharmacological properties, resolving the contradiction between efficacy and safety
2Reliability
If conventional antibodies are generated against CXCR7, then therapeutic interference is achieved, but low immunogenicity due to high conservation (96% mouse-human homology) limits effectiveness
Solution Approach 1:
The patent extracts the variable regions (VH, VHH) from conventional antibody structures, creating simplified yet highly specific binding units that maintain antigen recognition while reducing immunogenicity concerns associated with full-length antibodies
Solution Approach 2:
The patent uses phage display technology to create copies and variants of antibody variable regions, selecting for optimal binding affinity and specificity to CXCR7 while engineering reduced immunogenicity through sequence optimization
3Ease of manufacture
If the native conformation of active CXCR7 in cancer cells is not known, then selective anti-CXCR7 agent development is challenging, but this uncertainty prevents rational drug design
Solution Approach 1:
The patent performs preliminary structural characterization of CXCR7 using NMR spectroscopy and other biophysical methods to define the receptor's conformational states before optimizing antibody binders, enabling rational drug design despite initial uncertainties
Solution Approach 2:
The patent replaces traditional structural biology methods with NMR-based solution-state structural analysis, allowing characterization of CXCR7 dynamics and conformational states in near-physiological conditions to guide antibody design
4Reliability
If polypeptides with immunoglobulin single variable domains are used to target CXCR7, then specificity and half-life are improved, but structural complexity increases
Solution Approach 1:
The patent segments the antibody molecule into independent variable domains (VH, VHH) that can function autonomously, creating simplified structures with reduced complexity compared to full antibodies while maintaining binding specificity and extending half-life through Fc-independent mechanisms
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptides effectively inhibit CXCR7-mediated signaling, reduce tumor growth, and prolong anti-tumorigenic effects by specifically binding to CXCR7, offering a promising therapeutic approach for head and neck cancers with improved safety and efficacy.
Implementation Method 1
The polypeptides effectively inhibit CXCR7-mediated signaling, reduce tumor growth, and prolong anti-tumorigenic effects by specifically binding to CXCR7
Implementation Method 2
combined with serum albumin binding domains to enhance half-life and specificity
Data Source
AI summary
The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumor growth.